

**Cancer Committee**

**Std. 4.6: Pancreatic Adenocarcinoma Evaluation and Treatment review**

- Purpose:** Pancreatic Adenocarcinoma was selected as the site for which to analyze evaluation and treatment to ensure that treatment guidelines are met a high incidence of pancreatic adenocarcinoma was identified at Marshall Medical Center from the 2012 CNEXT site table compared to other cancers: 21/376 total cases.
- Data Selection Criteria** 21 patients identified in our CNEXT data registry with pancreatic adenocarcinoma diagnosis. Worksheets outlining the NCCN guidelines Version 1.2013 for Pancreatic Adenocarcinoma were created and filled out as thoroughly as possible for each patient to determine whether guidelines were met.
- Findings:** A chart review of the 21 patients was conducted by reviewers A.J. diVittorio, MD, Cancer Committee chair, B. Goldsmith, MD, Cancer Liaison Physician, and W. Goossen, CTR, Cancer Program Director.
- Stage distribution: Typical (53% at Stage IV)
  - Management was consistent with NCCN PANC work up and treatment
  - 19% underwent definitive surgery at high volume centers
  - 14% received chemoradiotherapy
  - 48% received chemo alone
- Other findings:
- One patient presented to the Emergency Department with atypical chest pain several months before diagnosis with advanced stage disease, suggesting heightened clinical suspicion in this setting (ACP and negative chest radiographic studies) and ordering of pancreatic protocol CT. This suggestion was presented at the Emergency Services Committee as well as the medical staff at large.
  - It would be useful to have capabilities for doing endoscopic ultrasound at MMC. MMC hopes to move forward with this suggestion.
- Reported to:** Cancer Committee September and December 2013; Medical Staff, Community
- Prepared by:** J. Buchanan, CPHQ, Quality Department, (530) 626-2770 x 2540